Clinical development on the frontier: gene therapy for duchenne muscular dystrophy

References

• Collins M, Thrasher A. Gene therapy: progress and predictions. Proc Biol Sci. 2015;282:20143003. [ PubMed: 26702034].
   PubMed Web of Science ®Google Scholar
• Friedmann T, Roblin R. Gene therapy for human genetic disease? Science. 1972;175:949–955. [ PubMed: 5061866].
   PubMed Web of Science ®Google Scholar
• Marshall E. Gene therapy death prompts review of adenovirus vector. Science. 1999;286:2244–2245. [ PubMed: 10636774].
   PubMed Web of Science ®Google Scholar
• Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4:346–358. [ PubMed: 12728277].
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348:255–256. [ PubMed: 12529469].
   PubMed Web of Science ®Google Scholar
• Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008;118:3143–3350. [ PubMed: 18688286].
   PubMed Web of Science ®Google Scholar
• Kaiser J. Gene therapy. Seeking the cause of induced leukemias in X-SCID trial. Science. 2003;299:495. [ PubMed: 12543948].
   PubMed Web of Science ®Google Scholar
• Kohn DB, Sadelain M, Glorioso JC. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer. 2003;3:477–488. [ PubMed: 12835668].
   PubMed Web of Science ®Google Scholar
• Yi Y, Hahm SH, Lee KH. Retroviral gene therapy: safety issues and possible solutions. Curr Gene Ther. 2005;5:25–35. [ PubMed: 15638709].
   PubMed Web of Science ®Google Scholar
• Naso MF, Tomkowicz B, Perry WL 3rd, et al. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs. 2017;31:317–334. [ PubMed: 28669112].
   PubMed Web of Science ®Google Scholar
• Balakrishnan B, Jayandharan GR. Basic biology of adeno-associated virus (AAV) vectors used in gene therapy. Curr Gene Ther. 2014;14:86–100. [ PubMed: 24588706].
   PubMed Web of Science ®Google Scholar
• Berns KI, Muzyczka N. AAV: an overview of unanswered questions. Hum Gene Ther. 2017;28:308–313. [ PubMed: 28335618].
   PubMed Web of Science ®Google Scholar
• US National Library of Medicine. ClinicalTrials.gov. [cited 2019 Nov 6]. Available from: https://clinicaltrials.gov/ct2/results?cond=&term=AAV&type=&rslt=&recrs=a&recrs=f&recrs=d&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&lupd_s=&lupd_e=&sort=
   Google Scholar
• Zaiss AK, Liu W, Bowen GP, et al. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol. 2002;76:4580–4590. [ PubMed: 11932423].
   PubMed Web of Science ®Google Scholar
• Colella P, Ronzitti G, Mingozzi F. Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev. 2017;8:87–104. PubMed: 29326962.
   PubMed Web of Science ®Google Scholar
• Valdmanis PN, Lisowski L, Kay MA. rAAV-mediated tumorigenesis: still unresolved after an AAV assault. Mol Ther. 2012;20:2014–2017. [ PubMed: 23131853].
   PubMed Web of Science ®Google Scholar
• Li H, Malani N, Hamilton SR, et al. Assessing the potential for AAV vector genotoxicity in a murine model. Blood. 2011;117:3311–3319. [ PubMed: 21106988].
   PubMed Web of Science ®Google Scholar
• Zincarelli C, Soltys S, Rengo G. Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008;16:1073–1080. [ PubMed: 18414476].
   PubMed Web of Science ®Google Scholar
• Kumar S, Markusic D, Biswas M, et al. Clinical development of gene therapy: results and lessons from recent successes. Mol Ther Methods Clin Dev. 2016;3:16034. [ PubMed: 27257611].
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA news release. FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss. [cited 2019 Nov 6]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-novel-gene-therapy-treat-patients-rare-form-inherited-vision-loss
   Google Scholar
• US Food and Drug Administration. FDA news release. FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality. [cited 2019 Nov 6]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease
   Google Scholar
• Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713–1722. [ PubMed: 29091557].
   PubMed Web of Science ®Google Scholar
• High KA, Roncarolo MG. Gene therapy. N Engl J Med. 2019;381:455–464. [ PubMed: 31365802].
   PubMed Web of Science ®Google Scholar
• Anguela XM, High KA. Entering the modern era of gene therapy. Annu Rev Med. 2019;70:273–288. [ PubMed: 30477394].
   PubMed Web of Science ®Google Scholar
• Al-Zaidy SA, Kolb SJ, Lowes L, et al. AVXS-101 (onasemnogene abeparvovec) for SMA1: comparative study with a prospective natural history cohort. J Neuromuscul Dis. 2019;6:307–317. [ PubMed: 31381526].
   PubMedGoogle Scholar
• Al-Zaidy SA, Mendell JR. From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1. Pediatr Neurol. 2019;100:3–11. [ PubMed: 31371124].
   PubMed Web of Science ®Google Scholar
• Lowes LP, Alfano LN, Arnold WD, et al. Impact of age and motor function in a phase 1/2A study of infants with SMA type 1 receiving single-dose gene replacement therapy. Pediatr Neurol. 2019;98:39–45. [ PubMed: 31277975].
   PubMed Web of Science ®Google Scholar
• Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390:849–860. [ PubMed: 28712537].
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA statement. Statement from FDA commissioner scott gottlieb, MD and Peter Marks, MD, PhD, director of the center for biologics evaluation and research on new policies to advance development of safe and effective cell and gene therapies. [cited 2019 Nov 6]. Available from: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-and-peter-marks-md-phd-director-center-biologics
   Google Scholar
• Human gene therapy for rare diseases – draft guidance for industry [Docket number:FDA-2018-D-2258]
   Google Scholar
• European Medicines Agency. Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products. [cited 2020 Jan 17]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-non-clinical-clinical-aspects-gene-therapy-medicinal-products_en.pdf
   Google Scholar
• Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7:27–31. [ PubMed: 27057123].
   PubMedGoogle Scholar
• Freeman MW, Dervan AP. The path from bench to bedside: considerations before starting the journey. J Investig Med. 2011;59:746–751. [ PubMed: 21441830].
   PubMed Web of Science ®Google Scholar
• Beall RF, Hwang TJ, Kesselheim AS. Pre-market development times for biologic versus small-molecule drugs. Nat Biotechnol. 2019;37:708–711. [ PubMed: 31213674].
   PubMed Web of Science ®Google Scholar
• Orphan Drug Act of 1983. Pub L. No. 97–414, 96 Stat. 2049.
   Google Scholar
• Benjamin K, Vernon MK, Patrick DL, et al. Patient-reported outcome and observer-reported outcome assessment in rare disease clinical trials: an ISPOR COA emerging good practices task force report. Value Health. 2017;20:838–855. [ PubMed: 28712612].
   PubMed Web of Science ®Google Scholar
• Mendell JR, Rodino-Klapac L, Shilling CJ. Path to clinical trials: trial design, development of the clinical product, and safety concerns in the implementation of clinical trials. In: Duan D, Mendell J, editors. Muscle Gene Therapy. Cham: Springer; 2019. p. 681–698.
   Google Scholar
• Draft Guidance for Industry. Considerations for the design of early-phase clinical trials of cellular and gene therapy products. Docket number: FDA-2013-D-0576.
   Google Scholar
• Cirak S, Arechavala-Gomeza V, Guglier M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet. 2011;378:595 ̶ 605. [ PubMed: 21784508].
   PubMed Web of Science ®Google Scholar
• Verhaart IE, Aartsma-Rus A. Gene therapy for Duchenne muscular dystrophy. Curr Opin Neurol. 2012;25:588–596. [ PubMed: 22892952].
   PubMed Web of Science ®Google Scholar
• Mendell JR, Lloyd-Puryear M. Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy. Muscle Nerve. 2013;48:21–26. [ PubMed: 23716304.
   PubMed Web of Science ®Google Scholar
• Mendell JR, Shilling C, Leslie ND, et al. Evidence based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol. 2012;71:304–313. [ PubMed: 22451200].
   PubMed Web of Science ®Google Scholar
• Garcia-Pelagio KP, Bloch RJ, Ortega A, et al. Biomechanics of the sarcolemma and costameres in single skeletal muscle fibers from normal and dystrophin-null mice. J Muscle Res Cell Motil. 2011;31:323–336. [ PubMed: 21312057].
   PubMed Web of Science ®Google Scholar
• Blaauw B, Agatea L, Toniolo L, et al. Eccentric contractions lead to myofibrillar dysfunction in muscular dystrophy. J Appl Physiol. 2010;108:105–111. [ PubMed: 19910334].
   PubMed Web of Science ®Google Scholar
• Petrof BJ, Shrager JB, Stedman HH, et al. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A. 1993;90:3710–3714. [ PubMed: 8475120].
   PubMed Web of Science ®Google Scholar
• Zubrzycka-Gaarn EE, Bulman DE, Karpati G, et al. The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle. Nature. 1988;333:466–469. [ PubMed: 3287171].
   PubMed Web of Science ®Google Scholar
• Zhao J, Kodippili K, Yue Y, et al. Dystrophin contains multiple independent membrane-binding domains. Hum Mol Genet. 2016;25:3647–3653. [ PubMed: 27378693].
   PubMed Web of Science ®Google Scholar
• Blake DJ, Weir A, Newey SE, et al. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev. 2002;82:291–329. [ PubMed: 11917091].
   PubMed Web of Science ®Google Scholar
• Bushby K, Connor E Clinical outcome measures for trials in Duchenne muscular dystrophy: report from international working group meetings. Clin Investig (Lond), Washington, DC. 2011;1:1217–1235. [ PubMed: 22639722]
   Google Scholar
• Cruz Guzman Odel R, Chavez Garcia AL, Rodriquez-Cruz M. Muscular dystrophies at different ages: metabolic and endocrine alterations. Int J Endocrinol. 2012;2012:485376. [PubMed: 22701119].
   PubMed Web of Science ®Google Scholar
• Brooke MH, Fenichel GM, Griggs RC, et al. Clinical investigation in Duchenne dystrophy: 2. determination of the “power” of therapeutic trials based on the natural history. Muscle Nerve. 1983;6:91–103. [PubMed: 6343858].
   PubMed Web of Science ®Google Scholar
• Le Guiner C, Servais L, Montus M, et al. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat Commun. 2017;8:16105. [PubMed: 28742067].
   PubMed Web of Science ®Google Scholar
• Audentes Therapeutics presents new positive data from ASPIRO, the clinical trial evaluating AT132 in patients with X-Linked myotubular myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle Society [press release]. San Francisco, CA: Business Wire; October 5, 2019.
   Google Scholar
• Potter RA, Griffin DA, Songergaard PC, et al. Systemic delivery of dysferlin overlap vectors provides long-term gene expression and functional improvement for dysferlinopathy. Hum Gene Ther. 2018;29:749–762. [PubMed: 28707952].
   PubMed Web of Science ®Google Scholar
• Rodino-Klapac LR, Janssen PM, Shontz KM, et al. Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model. Hum Mol Genet. 201315;22:3497–4929. [PubMed: 23863459].
   Web of Science ®Google Scholar
• Mendell JR, Sahenk Z, Lehman K, et al. Assessment of safety of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in Duchenne muscular dystrophy: a clinical trial. JAMA Neurol. 2019. Submitted.
   Google Scholar
• Rodino-Klapac LR, Janssen PM, Montgomery CL, et al. A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy. J Transl Med. 2007;5:45. [PubMed: 17892583].
   PubMed Web of Science ®Google Scholar
• Gao G, Vandenberghe LH, Alvira MR, et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol. 2004;78:6381–6388. [PubMed: 15163731].
   PubMed Web of Science ®Google Scholar
• Boutin S, Monteihet V, Veron P, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010;21:704–712. [PubMed: 20095819].
   PubMed Web of Science ®Google Scholar
• Louis Jeune V, Joergensen JA, Haijar RJ, et al. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods. 2013;24:59–67. [PubMed: 23442094].
   PubMed Web of Science ®Google Scholar
• Griffin DA, Potter RA, Pozsgai ER, et al. Adeno-associated virus serotype rh74 prevalence in muscular dystrophy population. Presented at the American Society of Gene and Cell Therapy (ASGCT) 22nd Annual Meeting. April 29-May 2, 2019. Washington, DC.
   Google Scholar
• Zygmunt DA, Crowe KE, Flanigan KM, et al. Comparison of serum rAAV serotype-specific antibodies in patients with Duchenne muscular dystrophy, Becker muscular dystrophy, inclusion body myositis, or GNE myopathy. Hum Gene Ther. 2017;28:737–746.
   PubMed Web of Science ®Google Scholar
• Salva MZ, Himeda CL, Tai PW, et al. Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol Ther. 2007;15:320–329. [PubMed: 17235310].
   PubMed Web of Science ®Google Scholar
• England SB, Nicholson LV, Johnson MA, et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature. 1990;343:180–182. [PubMed: 2404210].
   PubMed Web of Science ®Google Scholar
• Harper SQ, Hauser MA, DelloRusso C, et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med. 2002;8:253–261. [PubMed: 11875496].
   PubMed Web of Science ®Google Scholar
• Griffin DA, Heller KN, Shontz K, et al. Dose escalation study of systemically delivered AAVrh74.MHCK7.micro-dystrophin in the Mdx mouse model of DMD. [cited 2020 Jan 28]. Available from: https://www.cell.com/molecular-therapy-family/molecular-therapy/pdf/S1525-0016(18)30204-1.pdf
   Google Scholar
• Arora H, Willcocks RJ, Lott DJ, et al. Longitudinal timed function tests in Duchenne muscular dystrophy: imaging DMD cohort natural history. Muscle Nerve. 2018;58:631–638. [PubMed: 29742798].
   PubMed Web of Science ®Google Scholar
• Bello L, Morgenroth LP, Gordish-Dressman H, et al. DMD genotypes and loss of ambulation in the CINRG Duchenne natural history study. Neurology. 2016;87:401–409. [PubMed: 27343068].
   PubMed Web of Science ®Google Scholar
• McDonald CM, Gordish-Dressman H, Henricson EK, et al. Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: long-term natural history with and without glucocorticoids. Neuromuscul Disord. 2018;28:897–909. [PubMed: 30336970].
   PubMed Web of Science ®Google Scholar
• Pane M, Mazzone ES, Sivo S, et al. Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes. PLoS One. 2014;9:e108205. [PubMed: 25271887].
   PubMed Web of Science ®Google Scholar
• Roberto R, Fritz A, Hagar Y, et al. The natural history of cardiac and pulmonary function decline in patients with duchenne muscular dystrophy. Spine (Phila Pa 1976). 2011;36:E1009–E1017. [PubMed: 21289561].
   PubMed Web of Science ®Google Scholar
• Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77–93. [PubMed: 19945913].
   PubMed Web of Science ®Google Scholar
• Mendell JR, Campbell K, Rodino-Klapac L, et al. Dystrophin immunity in Duchenne’s muscular dystrophy. N Engl J Med. 2010;363:1429–1437. [PubMed: 20925545].
   PubMed Web of Science ®Google Scholar
• Chicoine LG, Montgomery CL, Bremer WG, et al. Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery. Mol Ther. 2014;22:338–347. [PubMed: 24196577].
   PubMed Web of Science ®Google Scholar
• Chicoine LG. Plasmapheresis enables robust micro-dystrophin expression following gene transfer in subjects with pre-existing immunity. Neurology. 2014;82(10suppl). P3.016. [cited 2020 Feb 5]. Available from: https://n.neurology.org/content/82/10_Supplement/P3.016/tab-article-info
   Google Scholar
• Hinderer C, Katz N, Buza EL, et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther. 2018;29:285–298. [PubMed: 29378426].
   PubMed Web of Science ®Google Scholar
• Binks M Early, initial data from C3391001, a first-in-human safety study of PF-06939926, a mini-dystrophin gene therapy for the potential treatment of DMD. Oral presentation at: Parent Project Muscular Dystrophy Annual Conference. June 2019; Orlando, FL. [cited 2019 Nov 6]. Available from: https://www.parentprojectmd.org/wp-content/uploads/2019/06/05_Fri_0950_Pfizer.pdf
   Google Scholar
• Laforet GA Oral presentation at: Parent Project Muscular Dystrophy Annual Conference. June 2019; Orlando, FL. [cited 2019 Nov 6]. Available from: https://www.parentprojectmd.org/wp-content/uploads/2019/06/04_Fri_0930_Solid.pdf
   Google Scholar
• Ehrhardt A, Xu H, Kay MA. Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in vivo. J Virol. 2003;77:7689–7695. [PubMed: 12805471].
   PubMed Web of Science ®Google Scholar
• Mendell JR, Chicoine LG, Al-Zaidy SA, et al. Gene delivery for limb-girdle muscular dystrophy type 2D by isolated limb infusion. Hum Gene Ther. 2019;30:794–801. [PubMed: 30838895].
   PubMed Web of Science ®Google Scholar
• Rodino-Klapac L, Pozsgai E, Lewis S, et al. Abstract 038: systemic gene transfer with rAAVrh74.MHCK7.SGCB increased β-sarcoglycan expression in patients with limb girdle muscular dystrophy type 2E. Neuromusc Disord. 2019;29(suppl1):S207.
   Google Scholar
• Gonin P, Gaillard C. Gene transfer vector biodistribution: pivotal safety studies in clinical gene therapy development. Gene Ther. 2004;11:S98–S108. [PubMed: 15454964].
   PubMed Web of Science ®Google Scholar
• Bruusgaard JC, Liestøl K, Ekmark M, et al. Number and spatial distribution of nuclei in the muscle fibres of normal mice studied in vivo. J Physiol. 2003;551(Pt 2):467–478. [PubMed: 12813146].
   PubMed Web of Science ®Google Scholar
• Pozsgai ER, Griffin DA, Heller KN, et al. Systemic AAV-mediated β-sarcoglycan delivery targeting cardiac and skeletal muscle ameliorates histological and functional deficits in LGMD2E mice. Mol Ther. 2017;25:855–869. [PubMed: 28284983].
   PubMed Web of Science ®Google Scholar
• Schnell FJ. Challenges of interpreting dystrophin content by western blot. US Neurol. 2019;15:40–46.
   Google Scholar
• Hulsker M, Verhaart I, van Vliet L, et al. Accurate dystrophin quantification in mouse tissue; identification of new and evaluation of existing methods. J Neuromuscul Dis]. 2016;3:77–90. [PubMed: 27854205.
   PubMedGoogle Scholar
• Ingram DS Oral presentation at: Parent Project Muscular Dystrophy Annual Conference. June 2019; Orlando, FL. [cited 2019 Nov 6]. Available from: https://www.parentprojectmd.org/wp-content/uploads/2019/06/06_Fri_1010_Sarepta.pdf
   Google Scholar
• Mendell JR, Sahenk Z, Lehman KJ, et al. Systemic gene transfer with rAAVrh74.MHCK7.micro-dystrophin in patients with Duchenne muscular dystrophy. Presented at the 17th Days of the French Society of Myology, November 20–22, 2019, Marseille, France.
   Google Scholar
• Bullock DG, McSweeney FM, Whitehead TP, et al. Serum creatine kinase activity and carrier status for Duchenne muscular dystrophy. Lancet. 1979;2:1370. [PubMed: 92710].
   PubMed Web of Science ®Google Scholar
• Ricotti V, Ridout DA, Pane M, et al. The northstar ambulatory assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. J Neurol Neurosurg Psychiatry. 2016;87:149–155. [PubMed: 25733532].
   PubMed Web of Science ®Google Scholar
• Pfizer presents initial clinical data on Phase 1b gene therapy study for Duchenne muscular dystrophy (DMD) [press release]. New York, NY: Pfizer Inc.; 2019 June 28. [cited 2020 Feb 5]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_presents_initial_clinical_data_on_phase_1b_gene_therapy_study_for_duchenne_muscular_dystrophy_dmd
   Google Scholar
• Solid Biosciences provides SGT-001 program update [press release]. Cambridge, MA: Solid Biosciences Inc.; 2019 November. [cited 2020 Feb 5]. Available from : https://investors.solidbio.com/news-releases/news-release-details/solid-biosciences-provides-sgt-001-program-update
   Google Scholar
• US Food and Drug Administration. FDA letter on BLA approval. [cited 2019 Dec 10]. Available from: https://www.fda.gov/media/126109/download
   Google Scholar